Abstract

We describe the design, kinetic properties, and structures of engineered subtilisin proteases that degrade the active form of RAS by cleaving a conserved sequence in switch 2. RAS is a signaling protein that, when mutated, drives a third of human cancers. To generate high specificity for the RAS target sequence, the active site was modified to be dependent on a cofactor (imidazole or nitrite) and protease sub-sites were engineered to create a linkage between substrate and cofactor binding. Selective proteolysis of active RAS arises from a 2-step process wherein sub-site interactions promote productive binding of the cofactor, enabling cleavage. Proteases engineered in this way specifically cleave active RAS in vitro, deplete the level of RAS in a bacterial reporter system, and also degrade RAS in human cell culture. Although these proteases target active RAS, the underlying design principles are fundamental and will be adaptable to many target proteins.

Chen et al. describe a rational design of subtilisin mutants that degrade active RAS by cleaving a conserved sequence in switch 2. They further modified the active site to be dependent on a cofactor to generate high target specificity. Proteases engineered to cleave this region degraded RAS in vitro and in cells with a promise of adaptability for other target proteins too.

Details

Title
Engineering subtilisin proteases that specifically degrade active RAS
Author
Chen, Yingwei 1 ; Toth, Eric A 2   VIAFID ORCID Logo  ; Ruan Biao 1 ; Choi, Eun Jung 1 ; Simmerman, Richard 1 ; Chen, Yihong 3 ; He, Yanan 3 ; Wang, Ruixue 3 ; Godoy-Ruiz, Raquel 4 ; King, Harlan 5   VIAFID ORCID Logo  ; Custer, Gregory 6   VIAFID ORCID Logo  ; Travis Gallagher D 7 ; Rozak, David A 8 ; Solomon Melani 6 ; Muro, Silvia 9 ; Weber, David J 10   VIAFID ORCID Logo  ; Orban, John 11 ; Fuerst, Thomas R 12   VIAFID ORCID Logo  ; Bryan, Philip N 13   VIAFID ORCID Logo 

 Potomac Affinity Proteins, North Potomac, USA (GRID:grid.423246.5) 
 Institute for Bioscience and Biotechnology Research, Rockville, USA (GRID:grid.423246.5); Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, USA (GRID:grid.411024.2) (ISNI:0000 0001 2175 4264); Center for Biomolecular Therapeutics, Rockville, USA (GRID:grid.411024.2) 
 Institute for Bioscience and Biotechnology Research, Rockville, USA (GRID:grid.423246.5) 
 Institute for Bioscience and Biotechnology Research, Rockville, USA (GRID:grid.423246.5); Center for Biomolecular Therapeutics, Rockville, USA (GRID:grid.423246.5); University of Maryland School of Medicine, Department of Biochemistry and Molecular Biology, Baltimore, USA (GRID:grid.411024.2) (ISNI:0000 0001 2175 4264) 
 Institute for Bioscience and Biotechnology Research, Rockville, USA (GRID:grid.411024.2); National Institute of Standards and Technology and the University of Maryland, Rockville, USA (GRID:grid.94225.38) (ISNI:000000012158463X) 
 Institute for Bioscience and Biotechnology Research, Rockville, USA (GRID:grid.94225.38); University of Maryland, Department of Bioengineering, College Park, USA (GRID:grid.164295.d) (ISNI:0000 0001 0941 7177) 
 Institute for Bioscience and Biotechnology Research, Rockville, USA (GRID:grid.164295.d); National Institute of Standards and Technology and the University of Maryland, Rockville, USA (GRID:grid.94225.38) (ISNI:000000012158463X) 
 Unified Culture Collection, United States Army Research Institute of Infectious Diseases, Fort Detrick, USA (GRID:grid.94225.38) 
 Institute for Bioscience and Biotechnology Research, Rockville, USA (GRID:grid.164295.d); University of Maryland, Department of Bioengineering, College Park, USA (GRID:grid.164295.d) (ISNI:0000 0001 0941 7177); Institute for Bioengineering of Catalonia of the Barcelona Institute of Science and Technology & Institution of Catalonia for Research and Advanced Studies, Barcelona, Spain (GRID:grid.424736.0) (ISNI:0000 0004 0536 2369) 
10  Institute for Bioscience and Biotechnology Research, Rockville, USA (GRID:grid.424736.0); Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, USA (GRID:grid.411024.2) (ISNI:0000 0001 2175 4264); Center for Biomolecular Therapeutics, Rockville, USA (GRID:grid.411024.2); University of Maryland School of Medicine, Department of Biochemistry and Molecular Biology, Baltimore, USA (GRID:grid.411024.2) (ISNI:0000 0001 2175 4264) 
11  Institute for Bioscience and Biotechnology Research, Rockville, USA (GRID:grid.411024.2); University of Maryland, Department of Chemistry and Biochemistry, College Park, USA (GRID:grid.164295.d) (ISNI:0000 0001 0941 7177) 
12  Institute for Bioscience and Biotechnology Research, Rockville, USA (GRID:grid.164295.d); University of Maryland, Department of Cell Biology and Molecular Genetics, College Park, USA (GRID:grid.164295.d) (ISNI:0000 0001 0941 7177) 
13  Potomac Affinity Proteins, North Potomac, USA (GRID:grid.423246.5); Institute for Bioscience and Biotechnology Research, Rockville, USA (GRID:grid.423246.5) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
23993642
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2497363526
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.